Core Viewpoint - The collaboration between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating strategic implementation processes [1][2] Group 1: Collaboration Details - A tripartite strategic cooperation agreement has been signed to establish the "LianKang-Wenzhou Medical University Translational Medicine Joint Innovation Laboratory" [1] - The collaboration will leverage each party's strengths in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization [2] Group 2: Research Focus - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair [1] - New formulations and delivery systems will be developed targeting diseases such as non-alcoholic steatohepatitis (NASH) and asthma, addressing significant unmet clinical needs in these areas [1] Group 3: Strategic Implications - This collaboration is expected to enhance the group's research efficiency and success rates in the biopharmaceutical innovation sector, shortening product development cycles [2] - The partnership will also facilitate the expansion of existing products into more clinical applications, reinforcing the group's competitive edge in the EGF/FGF niche [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into national-level innovation platforms, significantly accelerating the development and transformation of cutting-edge innovation pipelines [2]

Core Viewpoint - The strategic partnership between Link Health Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of the company's strategic initiatives [1][2] Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical translation and industrialization in the application of growth factor drugs in regenerative medicine [1][2] - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the goal of developing new compound formulations and delivery systems for diseases such as non-alcoholic steatohepatitis (NASH) and asthma [1][2] - This collaboration is expected to fill treatment gaps in multiple niche indications and unlock clinical and commercial value in the vast chronic disease market [1] Group 2 - The Wenzhou Medical University National Engineering Research Center is a leading independent entity focused on basic research and new drug development in the field of growth factor drugs, under the leadership of Academician Li Xiaokun from the Chinese Academy of Engineering [2] - The partnership is anticipated to enhance the company's R&D efficiency and success rate in the biopharmaceutical innovation sector, shorten product development cycles, and strengthen competitiveness in the EGF/FGF niche market [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into a national-level innovation platform, significantly accelerating the R&D and translation of cutting-edge innovation pipelines [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 聯康集團與溫醫大國家工程研究中心及 溫州市甌海區人民政府達成戰略合作 香港，二零二五年十二月三十日 — 聯康生物科技集團有限公司（「本公司」），連 同其附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，於近日在浙江省溫州 市，本集團與溫州醫科大學細胞生長因子藥物和蛋白製劑國家工程研究中心（「溫 醫 大 國 家 工 程 研 究 中 心 」）及 溫 州 市 甌 海 區 人 民 政 府 正 式 簽 署 三 方 戰 略 合 作 協 議 （「協議」），並就後續共建「聯康 — 溫醫大轉化醫學聯合創新實驗室（」「聯合實驗 室」）事宜進行探討。此次合作有助於強化本集團在皮膚 ...